Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection
Journal
Journal of Viral Hepatitis
Journal Volume
25
Journal Issue
12
Pages
1429-1437
Date Issued
2018
Author(s)
Younossi Z.M.
Stepanova M.
Henry L.
Han K.-H.
Ahn S.H.
Lim Y.-S.
Chuang W.-L.
Nguyen K.V.
Lai C.L.
Chan H.L.-Y.
Wei L.
Abstract
Although HCV infection is highly prevalent in East Asia, these patients have been underrepresented in HRQL studies. Here, we assess HRQL in East Asian HCV patients treated with different anti-HCV regimens. Patients completed Short Form-36 (SF-36) before, during and after treatment. A total of 989 HCV patients were enrolled in two phase 3 clinical trials [China: 60.2%, South Korea: 22.4%, Taiwan: 17.4%; genotype 1: 55.3%, treatment-na?ve: 57.5%; cirrhosis: 14.0%]. Patients received pegylated interferon, sofosbuvir and ribavirin (Peg-IFN?+?SOF?+?RBV; n?=?130, genotypes 1, 6) or SOF?+?RBV (n?=?475, all genotypes) or SOF and ledipasvir (LDV/SOF; n?=?384, genotype 1). The SVR-12 rates were 94.6%, 96.2% and 99.2%, respectively (P?=?0.005). During treatment, Peg-IFN?+?SOF?+?RBV-treated group experienced significant declines in most HRQL scores (by the end of treatment, mean decline up to ?12.0 points, all P?
Subjects
direct-acting antivirals; health-related quality of life; mental health; physical functioning; vitality
SDGs
Other Subjects
alanine aminotransferase; hemoglobin; ledipasvir; peginterferon; sofosbuvir; alpha interferon; antivirus agent; benzimidazole derivative; fluorene derivative; ledipasvir; ribavirin; sofosbuvir; adult; anemia; Article; body mass; drug safety; East Asian; fatigue; female; flu like syndrome; gastrointestinal symptom; genotype; hepatitis C; human; liver cell carcinoma; liver cirrhosis; major clinical study; male; mental disease; musculoskeletal disease; neurologic disease; non insulin dependent diabetes mellitus; phase 3 clinical trial (topic); prevalence; quality of life; questionnaire; Short Form 36; skin manifestation; sustained virologic response; virus load; aged; China; chronic hepatitis C; clinical trial; middle aged; multicenter study; phase 3 clinical trial; South Korea; Taiwan; treatment outcome; Adult; Aged; Antiviral Agents; Benzimidazoles; China; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Quality of Life; Republic of Korea; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Taiwan; Treatment Outcome
Publisher
Blackwell Publishing Ltd
Type
journal article